RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
  Brain Diseases
  Demyelinating Diseases
  Headache
   Tension Headache
  Memory
  Neurochemistry
  Neurodegenerative Diseases
  Regeneration
  Spinal Cord Diseases
  Stroke
  Taste
  Trigeminal Neuralgia
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Sep 15, 2017 - 4:49:58 AM
Headache Channel

subscribe to Headache newsletter
Latest Research : Neurosciences : Headache

   EMAIL   |   PRINT
Treating chronic migraine with Botox

Aug 30, 2011 - 11:44:46 AM

The treatment is suitable for chronic migraine sufferers in the 18-80 years age group.


 
[RxPG] The anti-ageing drug Botox was until now an answer to your beauty concerns, but now the treatment can also benefit sufferers of chronic migraine, a neurological disorder characterised by severe headaches, say experts.

Chronic migraine can leave sufferers in pain for at least half of every month. The World Health Organization - ranks migraine as the 19th most disabling disease and notes that a day lived with severe migraine can be more disabling than blindness, paraplegia, angina or rheumatoid arthritis. Although these debilitating headaches occur in both men and women, women are believed to be three times more likely than men to suffer from migraines.

Patients of migraine often experience anxiety and depression along with the headaches. Stress, dietary, sleeping and other inappropriate lifestyle habits are known to influence the state of chronic migraine sufferers. Now studies and clinical trials have revealed that when injected in labelled doses and in the recommended locations in the head and neck, Botox is expected to produce results lasting up to three months depending on the individual patient.

'Since using Botox for chronic migraines is a relatively new treatment on the block, many people are still not aware of it and most do not understand it well, but the response that I have received from my patients has been very good. This will surely pick up in years to come,' Sumit Singh, senior consultant, headache & movement disorder, Medanta - The Medicity, Gurgaon, told IANS on the phone.

'Botox treatment is just evolving in our country. At this moment, there is not enough data on the number of patients being treated with it for their condition. However, it surely seems to be catching up and is well-received by our patients. The treatment will become popular in coming years,' echoed Rajashekar Reddi, senior consultant neurologist, Max Hospitals, New Delhi.

For the treatment of chronic migraine, measured doses of Botox are injected at 29-32 sites in a patient. These sites include six-seven on the forehead, eight on the temples and six each on the back of the head, the neck and the shoulders. It takes 10-15 minutes to administer the dosage. Besides, two additional sites - the temples or the back of the head on each side - can also be injected, depending upon whether extreme pain is felt by the patient at these sites.

Although there aren't any major side effects of the treatment, patients may feel slight pain around the injected areas.

'When the drug is injected by an expert, the chances of any side-effects are negligible. Usually, there occurs slight pain and bruising at the site of injection,' said Charulata Sankhla, senior consultant, neurology, Hinduja Hospital, Mumbai.

'There are mild and transient side-effects such as drooping of eyelids that is observed when the wrong or an overenthusiastic dose of Botox is administered to the patient,' added Reddi.

Although the treatment lasts for up to three months, it doesn't come very cheap. Including the procedural fee and the drug costs, the price of this treatment is about Rs.25,000.

The treatment is already making its mark in big cities like Mumbai, Bangalore, Delhi and Kolkata but is yet to find a following in the smaller ones.

'It is available in all the bigger medical centres/hospitals in major cities, including the metros. Patients in Tier-2 cities are yet to be sensitised about this treatment as it is not available there,' revealed Reddi.

The treatment is suitable for chronic migraine sufferers in the 18-80 years age group.

-



Related Headache News
Treating chronic migraine with Botox
Genes linked to migraine discovered - TRPM8, LRP1 and PRDM16
Repeated migraines and headaches do not increase the risk of cognitive decline
New visual pathway linked to photophobia in migraines identified
Tai Chi may help alleviate tension headaches
RAMP - the protein implicated in causing migraines
Migraine dealings for the women
Electronic TMS Device Zaps Migraine
Tension Headache May Actually Be TMJD
Tension headaches - Don't ignore this differential diagnosis

Subscribe to Headache Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

Online ACLS Certification

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)